Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran [Yahoo! Finance]
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: Yahoo! Finance
On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, a step that could help accelerate its development and review timeline. On April 6, 2026, Jefferies lowered its price target on Arbutus Biopharma Corporation (NASDAQ:ABUS) to $5.50 from $7 while maintaining a Buy rating, citing updated assumptions around the outcome of Moderna's appeal tied to their legal settlement. The firm raised its estimated probability of Moderna prevailing under 28 U.S.C. Section 1498 to 75% from 25%, which would impact the contingent $1.3B payment. Last month, Arbutus and Genevant Sciences, a subsidiary of Roivant Sciences, reached a global settlement with Moderna valued at up to $2.25B related to the use of lipid nanoparticle (LNP) technology in COVID-19 vaccines. The agreement includes a $950M upfront payment scheduled for July 2026 and an additional $1.3B contingent on the appellate r
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Moderna's Quarterly Earnings Preview: What You Need to Know [Yahoo! Finance]Yahoo! Finance
- Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability [Yahoo! Finance]Yahoo! Finance
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis BGlobeNewswire
- Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M [Seeking Alpha]Seeking Alpha
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
ABUS
Earnings
- 8/6/25 - Beat
ABUS
Sec Filings
- 4/15/26 - Form 8-K
- 4/14/26 - Form DEFA14A
- 4/14/26 - Form DEF
- ABUS's page on the SEC website